
Neurocrine Biosciences (NBIX) Stock Forecast & Price Target
Neurocrine Biosciences (NBIX) Analyst Ratings
Bulls say
Neurocrine Biosciences Inc is poised for growth due to an increasing patient population for congenital adrenal hyperplasia (CAH), which has expanded by 3,000 patients since 2018, indicating a rising demand for targeted treatments. The company's product Crenessity has the potential to significantly reduce the clinical consequences of androgen excess, suggesting a valuable addition to its treatment offerings in managing related complications. Additionally, a focus on educating prescribers and improving access will likely enhance market penetration and sustain the momentum of product launches, further supporting a positive long-term outlook for the company's stock.
Bears say
Neurocrine Biosciences faces a negative outlook primarily due to a downward revision in its revenue assumptions for the drug Ingrezza, which now reflects challenges such as slower growth, competitive pressures, and complexities in payer dynamics, reducing the anticipated revenue from $2,846 million to $2,648 million by the end of 2025. Additionally, the company is exposed to significant risks that could impact its investment thesis, including potential failures in clinical studies, the inability to secure regulatory approvals, and the threat of a smaller-than-expected commercial opportunity stemming from market size and competition. These factors collectively contribute to concerns regarding the overall financial performance and growth prospects of Neurocrine Biosciences.
This aggregate rating is based on analysts' research of Neurocrine Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Neurocrine Biosciences (NBIX) Analyst Forecast & Price Prediction
Start investing in Neurocrine Biosciences (NBIX)
Order type
Buy in
Order amount
Est. shares
0 shares